Free tool
FAERS Monitor: Novolog Mix 70/30 Penfill
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 021172 or its brand name (Novolog Mix 70/30 Penfill, Insulin Aspart Protamine Recombinant, Insulin Aspart Recombinant). Reports on generic versions are filed under their own applications.
Reports
12,980
Serious
10,763
83% of reports
Hospitalization
6,414
Death reported
1,506
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- blood glucose increased1,265
- nausea839
- dyspnoea793
- hypoglycaemia737
- vomiting698
- off label use645
- drug ineffective532
- diarrhoea522
- condition aggravated504
- abdominal pain500
- fatigue486
- dizziness451
- acute kidney injury448
- blood glucose decreased423
- pneumonia423
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 65 |
| 2005 | 95 |
| 2006 | 155 |
| 2007 | 243 |
| 2008 | 313 |
| 2009 | 308 |
| 2010 | 215 |
| 2011 | 236 |
| 2012 | 280 |
| 2013 | 225 |
| 2014 | 277 |
| 2015 | 515 |
| 2016 | 526 |
| 2017 | 573 |
| 2018 | 670 |
| 2019 | 622 |
| 2020 | 790 |
| 2021 | 1,050 |
| 2022 | 1,158 |
| 2023 | 1,047 |
| 2024 | 1,159 |
| 2025 | 1,440 |
| 2026 | 1,018 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,041,179 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hypoglycaemiaSignal | 737 | 25.0 | 23.3 | 16,728 |
| blood glucose decreasedSignal | 423 | 14.4 | 13.1 | 5,223 |
| blood glucose increasedSignal | 1,265 | 10.9 | 10.4 | 11,449 |
| acute kidney injurySignal | 448 | 4.8 | 4.3 | 1,330 |
| abdominal painSignal | 500 | 3.5 | 3.2 | 893 |
| condition aggravatedSignal | 504 | 2.7 | 2.5 | 540 |
| vomitingSignal | 698 | 2.4 | 2.2 | 585 |
| dyspnoeaSignal | 793 | 2.3 | 2.1 | 578 |
| pneumoniaSignal | 423 | 2.1 | 1.9 | 252 |
| nausea | 839 | 1.7 | 1.6 | 261 |
| dizziness | 451 | 1.5 | 1.3 | 68 |
| diarrhoea | 522 | 1.3 | 1.2 | 39 |
| off label use | 645 | 1.2 | 1.1 | 21 |
| fatigue | 486 | 1.0 | 0.9 | 0 |
| drug ineffective | 532 | 0.7 | 0.6 | 104 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.